Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies
Velia Chiara Di Maio(University of Rome Tor Vergata), Francesca Ceccherini‐Silberstein(University of Cologne), Valeria Cento(Rostov State Medical University), Antonio Grieco(Università Cattolica del Sacro Cuore), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Pierluigi Tarquini(Nini Hospital), Adriano Pellicelli(Carlo Forlanini Hospital), M. Paoloni, Giuliano Rizzardini, Elisabetta Teti(University of Rome Tor Vergata), Loredana Sarmati(University of Rome Tor Vergata), Vincenza Calvaruso(University of Palermo), M. Melis(University of Sassari), Simona Landonio(ASST Fatebenefratelli Sacco), Claudio Maria Mastroianni(Sapienza University of Rome), M. Aragri(University of Rome Tor Vergata), C. Pasquazzi(Azienda Ospedaliera Sant'Andrea), Sergio Babudieri(University of Sassari), Gabriella Verucchi(University of Bologna), S. Francioso, Ada Bertoli(IRCCS Policlinico San Donato), Ilaria Lenci, Francesco Santopaolo(University of Rome Tor Vergata), Gloria Taliani(Sapienza University of Rome), M. Angélico, Chiara Masetti(NHS Blood and Transplant), Massimo Andreoni(University of Rome Tor Vergata), Dante Romagnoli(University of Modena and Reggio Emilia), F.P. Antonucci(University of Rome Tor Vergata), N. Caporaso(Federico II University Hospital), Giustino Parruti(Azienda USL di Pescara), Valeria Micheli(ASST Fatebenefratelli Sacco), Raffaele Cozzolongo, Manuela Merli(Policlinico Umberto I), Elisabetta Loggi(University of Bologna), Maria Concetta Bellocchi(University of Rome Tor Vergata), Silvia Barbaliscia(University of Rome Tor Vergata), Jacopo Vecchiet(University of Chieti-Pescara), Carlo Federico Perno(Centre International De Reference Chantal Biya), Antonio Craxı̀(University of Palermo), Giuseppina Brancaccio, Laura Gianserra(Azienda Ospedaliera Sant'Andrea), A. Picciotto(University of Genoa), Piera Rossi(University of Rome Tor Vergata), Vincenzo Vullo(Policlinico Umberto I), Valeria Pace Palitti(Azienda USL di Pescara), C. Magni(ASST Fatebenefratelli Sacco), Filomena Morisco, Massimo Siciliano(Università Cattolica del Sacro Cuore), Antonio Di Biagio
Cited by 90
Related Papers
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†
|Hepatology|2009|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
|Journal of Hepatology|2018|1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821